Abstract 1138P
Background
Non-melanoma skin cancers (NMSC), including squamous cell carcinoma (SCC) and basal cell carcinoma (BCC), are the most common forms of skin cancer, with a rising incidence due to deficient sun protection and growing life expectancy. Treatment options include surgery, radiotherapy, immunotherapy, targeted therapy, or chemotherapy. Surgery typically offers high cure rates; however, surgery's suitability and/or effectiveness in certain patients (pts) may be limited by disease factors (location, functional and cosmetic impairment) or pts factors (age, comorbidities, personal preferences). Initial intralesional treatment with immunostimulatory drugs may be another therapeutic approach, potentially curing NMSC or making surgery less invasive. Here we investigate a combination of 2 immune cytokines (Bifikafusp alfa (L19IL2) and Onfekafusp alfa (L19TNF) targeting the extra domain B of fibronectin (EDB) for selective delivery of immunostimulatory payloads to the tumor site. EDB is virtually absent in healthy adult tissues but highly expressed in tumors, including NMSC.
Methods
In a single-arm, ongoing, phase II study (NCT04362722), pts with locally advanced, non-metastatic, node-negative, single or multifocal NMSC, not eligible for surgery or radiotherapy or who refuse it, are treated with 4 weekly intratumoral administrations of L19IL2/IL19TNF. 14 pts (11 BCC and 3 cSCC) have been treated and are evaluable for safety and efficacy.
Results
Administration of L19IL2/L19TNF was well tolerated with no grade 4-5 adverse events (AE). The most common treatment-related AEs were flu-like symptoms (36.4%), pyrexia (27.3%), face edema, chills, and injection site reaction (13.6%), all transient, managed with symptomatic therapy. In BCC cohort, ORR was assessed on day 36 with a 27.3% RR. In the follow-up, 5/11pts achieved pathological complete response (pCR) with an average time to pCR of 66 days from the first administration. In the 3 SCC pts, ORR was 33.3 % with 1 pCR.
Conclusions
The tolerable safety profile of L19IL2/L19TNF and the results obtained in pts with NMSC justify further exploring the potential of intralesional administration of immunostimulatory drugs in this setting.
Clinical trial identification
EudraCT 2020-003299-42, NCT 04362722.
Editorial acknowledgement
Legal entity responsible for the study
Philogen SpA.
Funding
Philogen SpA.
Disclosure
L. Flatz: Financial Interests, Personal, Stocks or ownership: Hookipa Pharma; Financial Interests, Personal, Invited Speaker: BMS, Novartis, Sanofi; Financial Interests, Personal, Advisory Board: BMS, Novartis, Sanofi, Philogen; Financial Interests, Institutional, Research Funding: Hookipa Pharma; Financial Interests, Personal, Royalties: Hookipa Pharma. U. Leiter-Stoppke: Financial Interests, Institutional, Research Grant: MSD; Financial Interests, Personal, Invited Speaker: MSD, Novartis, Sun Pharma, Allmiral Hermal, Sanofi; Financial Interests, Personal, Other, Travel Support: Sun Pharma; Financial Interests, Personal, Advisory Board: MSD, Novartis, Sun Pharma, Allmiral Hermal, Sanofi; Financial Interests, Personal, Member, Board member: ADO (DECOG). N. wagner: Financial Interests, Personal, Speaker, Consultant, Advisor: Novartis, Sanofi; Financial Interests, Personal, Advisory Board: Pierre Fabre; Other, Personal and Institutional, Principal Investigator: Sanofi, Regeneron, Pierre Fabre, Philogen; Other, Personal, Member: SITC; Financial Interests, Personal, Other, Travel Support: Amgen. L. Nadal, E. Puca, G. Elia: Financial Interests, Personal, Officer, Employee: Philogen S.p.A. A. Covelli: Financial Interests, Personal, Other, Member of the Scientific Board: Cellestia Biotech AG, Basel, Italfarmaco S.p.A., Milano, Peptomyc S.L, Barcelona; Financial Interests, Personal, Officer, Chief Medical Officer: Philogen S.p.A., Siena. D. Neri: Financial Interests, Personal, Member of Board of Directors: Philogen S.p.A; Financial Interests, Personal, Stocks or ownership: Philogen S.p.A. C. Antonio: Financial Interests, Personal, Advisory Board: AbbVie, Sanofi, Eli Lilly, Philogen. T.M.S. Amaral: Financial Interests, Personal, Writing Engagement: CeCaVa; Financial Interests, Personal, Invited Speaker: BMS, Novartis, Pierre Fabre; Financial Interests, Institutional, Funding: Novartis, Neracare, Sanofi, Skyline-Dx; Financial Interests, Institutional, Research Grant: Novartis, iFIT; Financial Interests, Institutional, Local PI: IO Biotech, MSD, University Hospital, Essen, Roche; Financial Interests, Institutional, Coordinating PI: Unicancer; Non-Financial Interests, Member: Portuguese Society for Medical Oncology, ASCO; Other, Clinical expert: Infarmed. All other authors have declared no conflicts of interest.
Resources from the same session
1129P - Effect of subsequent therapies including checkpoint inhibitors on overall survival in a phase III randomized trial of tebentafusp in first-line metastatic uveal melanoma: Long-term follow-up
Presenter: Marlana Orloff
Session: Poster session 13
1130P - Tebentafusp (tebe) in an ongoing cohort of 72 French patients (pts) with metastatic uveal melanoma (mUM)
Presenter: Leah Mailly-Giacchetti
Session: Poster session 13
1131P - Management of metastatic uveal melanoma (MUM) patients on tebentafusp in a real-world setting
Presenter: Mauricio Fernando Ribeiro
Session: Poster session 13
1132P - Chemokine expression in uveal melanoma and association with tumor genetics and response to immunotherapy
Presenter: Aparna Nallagangula
Session: Poster session 13
1133P - SF3B1 mutation predicts improved overall survival in metastatic uveal melanoma patients: Molecular and clinical correlates
Presenter: Luis del Carpio Huerta
Session: Poster session 13
1134P - Safety and efficacy of low dose (LD) ipilimumab (Ipi) + pembrolizumab (pem) in checkpoint inhibitor (CPI) naïve patients (pts) with melanoma brain metastases (MBM)
Presenter: Isabella Glitza
Session: Poster session 13
1135P - Comparison of intracranial (IC) response assessment criteria in patients (pts) with melanoma brain metastases (MBM) treated with combination nivolumab (NIVO) plus ipilimumab (IPI) in CheckMate 204
Presenter: Raymond Huang
Session: Poster session 13
1136P - Regorafenib combined with BRAF-/MEK-inhibitors for the treatment of refractory melanoma brain metastases
Presenter: Iris Dirven
Session: Poster session 13
1139P - Final results of a phase II study of pembrolizumab as first-line treatment in advanced cutaneous squamous cell carcinomas (CSCCs)
Presenter: Eve Maubec
Session: Poster session 13